Comment: Doxycycline vs Vancomycin for the Treatment of MRSA-Associated Acute Pulmonary Exacerbations in People With Cystic Fibrosis

Abstract

Get full access to this article

View all access options for this article.

References

Brickel

Kelley

Jaso

, et al. Doxycycline versus vancomycin for the treatment of MRSA-associated acute pulmonary exacerbations in people with cystic fibrosis. Ann Pharmacother. 2025;59(8):685-693. doi:10.1177/10600280241310595

Barry

Mall

Alvarez

, et al. Triple therapy for cystic fibrosis Phe508del-gating and -residual function genotypes. N Engl J Med. 2021;385:815-825. doi:10.1056/NEJMoa2100665

Abdalla

Bratcher

, et al. Doxycycline improves clinical outcomes during cystic fibrosis exacerbations. Eur Respir J. 2017;49(4):1601102. doi:10.1183/13993003.01102-2016

Beringer

Owens

Nguyen

Benitez

Rao

D’Argenio

DZ.

Pharmacokinetics of doxycycline in adults with cystic fibrosis. Antimicrob Agents Chemother. 2012;56(1):70-74. doi:10.1128/AAC.05710-11